Skip to main content
Full access
Letter to the Editor
Published Online: 1 June 2001

SSRIs and Mammoplasia

Publication: American Journal of Psychiatry
To the Editor: Mammoplasia (1), nonpuerperal lactation (2), and aggravation of preexisting fibrocystic disease (3) have all been reported in association with the use of selective serotonin reuptake inhibitors (SSRIs). Mammographic changes associated with SSRI use have not been reported previously, to my knowledge. This report is a description of a woman who had mammographic changes during treatment with an SSRI.
Ms. A, a 43-year-old woman with a history of dysthymia and major depression, had a normal baseline mammogram at age 35 and a normal repeat mammogram at age 40. There was no history of fibrocystic disease. Her menstrual periods were regular. She had gained approximately 6 lb and had subjective breast enlargement as a result of fluvoxamine therapy. Approximately 8 months after starting to take fluvoxamine, 50–100 mg/day, she had another routine mammogram.
The mammogram was interpreted as having “bilateral hyperdensities,” and Ms. A was referred to a breast surgeon for consultation. No masses were found during palpation, and a 6-month follow-up mammogram was recommended. Ms. A chose to stop taking fluvoxamine because of concern that the mammoplasia and mammographic changes were related. A non-SSRI antidepressant was substituted, and her breasts returned to normal size. A 6-month follow-up mammogram was normal.
Mammoplasia during SSRI therapy was reported in up to 39% of patients in one study (1). The rate of mammoplasia was unrelated to age, menopausal status, or duration of treatment. Mammoplasia was associated with weight gain in 84% of the patients, and weight gain without mammoplasia occurred in 30% of the patients (1). Serotonergic antidepressants are associated with a risk of nonpuerperal lactation approximately eight times as high as the risk with other antidepressants (2).
These effects are probably mediated by indirect inhibition of dopamine transmission by serotonin. As dopamine is inhibited, prolactin release is disinhibited. This report illustrates that SSRIs may cause not only mammoplasia but also mammographic changes. Clinicians should be aware of this possibility, because this effect can result not only in significant anxiety for the patient but also in referral for consultation with breast specialists who may not be aware of this association.
The clinical significance of these effects is not known. Concern has grown about the long-term risks for women of nonpuerperal elevation of prolactin levels, especially for those with a family history of breast cancer. Research is needed to assess if mammographic changes occur regularly along with mammoplasia associated with SSRI use and whether there are long-term risks associated with SSRI-induced mammoplasia.

References

1.
Amsterdam JD, Garcia-Espana F, Goodman D, Hooper M, Hornig-Rohan M: Breast enlargement during chronic antidepressant therapy. J Affect Disord 1997; 46:151–156
2.
Egberts ACG, Meyboom RH, de Koning FH, Bakker A, Leufkens HG: Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol 1997; 44:277–281
3.
McKenzie LJ, Risch SC: Fibrocystic breast disease following treatment with selective serotonin reuptake inhibitors (letter). Am J Psychiatry 1995; 152:471

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 967
PubMed: 11384918

History

Published online: 1 June 2001
Published in print: June 2001

Authors

Affiliations

PAULA MARCUS, M.D.
Larchmont, N.Y.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share